Acthar Gel

Autoimmune Diseases

Toyos ClinicPhase 4 / ApprovedActive

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

18 Active assets in the Autoimmune Diseases cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide The Children's Hospital of Zhejiang University School of Medicine	Phase 2	B
Cephalexin Mayo Clinic	Phase 4	B
CEFADROXIL ANHYDROUS Mayo Clinic	Phase 4	B
Doxycycline Mayo Clinic	Phase 4	B
FILGRASTIM Johns Hopkins University	Phase 2	B

View all 24 →

Same molecule, other indications

Acthar Gel is also rated in:

Dry EyeDormant

B

Indicative ·

60 / 100

Neurotrophic KeratitisDormant

B

Indicative ·

60 / 100

Multiple Sclerosis, Relapsing-RemittingDormant

B

Indicative ·

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.